Recurrent Adult Soft Tissue Sarcoma Clinical Trial
Official title:
A Phase 1b/2 Study of Imatinib in Combination With Everolimus in Synovial Sarcoma
Verified date | June 2013 |
Source | National Cancer Institute (NCI) |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
This phase I/II clinical trial is studying the side effects and best dose of everolimus when given with imatinib mesylate and to see how well they work in treating patients with locally advanced, locally recurrent or metastatic soft tissue sarcoma. Everolimus and imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Status | Completed |
Enrollment | 14 |
Est. completion date | October 2013 |
Est. primary completion date | October 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Histologically or cytologically confirmed synovial sarcoma that is platelet-derived growth factor receptor, alpha polypeptide positive (PDGFRA+) - Metastatic and/or locally advanced or locally recurrent disease - Patients must consent to tumor biopsies before therapy and after the second week of therapy - Patients who do not have accessible tumor for biopsy may be enrolled at the discretion of the principal investigator - Patients must have measurable disease, by RECIST 1.1, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as = 20 mm by conventional techniques or as = 10 mm by spiral CT scan - Tumor lesions that are situated in a previously irradiated area may be considered measurable for the purposes of this study only if there is evidence of growth of the area following a course of irradiation that cannot be attributed to necrosis or bleeding into the tumor - Patients with brain metastasis that has been treated with definitive surgery or radiotherapy, and who have been clinically stable for 3 months following the procedure with no neurological signs or symptoms and no requirement for systemic glucocorticoids, are eligible for study - ECOG performance status 0-1 - Life expectancy greater than 3 months - ANC = 1,500/mm³ - Platelet count = 75,000/mm³ - Total bilirubin = 1.5 times upper limit of normal (ULN) (except for patients with known Gilbert syndrome) - AST/ALT = 3 times ULN - Serum creatinine = 1.5 times ULN - Serum glucose = 120 mg/dL - Total cholesterol < 300 mg/dL - Triglycerides < 2.5 times ULN - Not pregnant or nursing - Negative pregnancy test - Women of child-bearing potential and men must agree to use adequate contraception (hormonal, barrier method of birth control, or abstinence) during therapy and for at least 8 weeks after completion of therapy - Patients must not have current evidence of another malignancy - No history of allergic reactions attributed to compounds of similar chemical or biologic composition to everolimus, imatinib mesylate, or other agents used in the study - No uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, including HIV, active hepatitis B or C, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, poorly controlled diabetes, or psychiatric illness/social situations that would limit compliance with study requirements - No patients with significant compromised respiratory problems or an active and unexplained pneumonitis - No concurrent combination antiretroviral therapy for HIV-positive patients - At least 4 weeks since any number of prior chemotherapy regimens (6 weeks for carmustine or mitomycin C) for recurrent/metastatic disease - No prior tyrosine kinase inhibitors - Recovered to = grade 1 NCI CTCAE version 4 adverse events related to prior tumor-specific therapy - No patients who have had major surgery within the past 4 weeks, or who have not recovered from adverse events to = grade 1 NCI CTCAE adverse events associated with surgery - Surgical changes not expected to improve ( e.g., removal of muscle tissue) allowed - No prior mTOR inhibitors, such as sirolimus, everolimus, ridaforolimus, or temsirolimus - No other concurrent investigational agents |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Memorial Sloan-Kettering Cancer Center | New York | New York |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Response Rate (CR + PR) Assessed by RECIST 1.1 (Phase II) | At 8 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00245102 -
Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
|
Phase 2 | |
Completed |
NCT01222715 -
Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma
|
Phase 2 | |
Completed |
NCT01206140 -
Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery
|
Phase 2 | |
Completed |
NCT01553539 -
Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
|
Phase 2 | |
Completed |
NCT00098579 -
Doxorubicin Hydrochloride and Alvocidib in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery
|
Phase 1 | |
Completed |
NCT00004241 -
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
|
Phase 1 | |
Completed |
NCT01462630 -
Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma
|
Phase 2 | |
Completed |
NCT01016015 -
Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma
|
Phase 2 | |
Completed |
NCT00084630 -
Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans
|
Phase 2 | |
Terminated |
NCT00087191 -
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
|
N/A | |
Completed |
NCT01782313 -
A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas
|
Phase 2 | |
Completed |
NCT02357810 -
Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas
|
Phase 2 | |
Terminated |
NCT00233948 -
Nelfinavir Mesylate in Treating Patients With Recurrent, Metastatic, or Unresectable Liposarcoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01552434 -
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
|
Phase 1 | |
Completed |
NCT00919269 -
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma
|
||
Completed |
NCT01532687 -
Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma
|
Phase 2 | |
Completed |
NCT01154452 -
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
|
Phase 1/Phase 2 | |
Completed |
NCT00937495 -
Vorinostat and Bortezomib in Treating Patients With Advanced Soft Tissue Sarcoma
|
Phase 2 | |
Completed |
NCT00720174 -
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
|
Phase 1 | |
Completed |
NCT00330421 -
Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07)
|
Phase 2 |